New Two-Pronged immune attack joins fight against advanced rectal cancer
NCT ID NCT06787183
Summary
This study is testing a new combination treatment for people whose rectal cancer has spread to the liver. It combines a short, intense course of radiation with standard chemotherapy and a new type of immunotherapy drug (QL1706) that targets the immune system in two ways. The goal is to see if this approach is more effective at controlling the cancer and preventing it from growing than current treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER WITH LIVER METASTASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Fuzhou First General Hospital
NOT_YET_RECRUITINGFuzhou, Fujian, 350004, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.